R&G PharmaStudies Co

R&G PharmaStudies Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of R&G PharmaStudies Co (301333.SZ) as of Oct 15, 2026 is 135.02 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 133.16 M CNY — a change of 1.40% (higher).

EBITDA

135.02 MCNY

YoY

1.40%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of R&G PharmaStudies Co is 2025 135.02 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of R&G PharmaStudies Co was 2024 133.16 M CNY. It decreases by 1.40% higher compared to the previous year.

The R&G PharmaStudies Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
101.43 M CNY
Jan 1, 2020
104.91 M CNY
Jan 1, 2021
123.40 M CNY
Jan 1, 2022
115.43 M CNY
Jan 1, 2023
151.58 M CNY
Jan 1, 2024
133.16 M CNY
Jan 1, 2025
135.02 M CNY
The R&G PharmaStudies Co EBITDA history
YEAREBITDAYoY
135.02 MCNY+1.40%
133.16 MCNY-12.16%
151.58 MCNY+31.32%
115.43 MCNY-6.45%
123.40 MCNY+17.62%
104.91 MCNY+3.43%
101.43 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

R&G PharmaStudies Co Stock analysis

What does R&G PharmaStudies Co do? R&G PharmaStudies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about R&G PharmaStudies Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of R&G PharmaStudies Co is 135.02 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of R&G PharmaStudies Co changed from 133.16 M CNY to 135.02 M CNY, representing a 1.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) R&G PharmaStudies Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s R&G PharmaStudies Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — R&G PharmaStudies Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — R&G PharmaStudies Co